FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations. FLT3 in AML: Much more to learn about biology and optimal targeting

Francis J. Giles*

*Corresponding author for this work

Research output: Contribution to journalEditorial

2 Scopus citations

Abstract

Aberrant FLT3 function in leukemia blasts is associated with a poor prognosis. A number of FLT3 modulators are in development. FLT3 mutations may synergistize with other molecular abnormalities in myeloid transformation. Further insights into FLT3 biology are needed to optimally study the therapeutic role of FLT3 inhibitors.

Original languageEnglish (US)
Pages (from-to)1469-1470
Number of pages2
JournalLeukemia Research
Volume30
Issue number12
DOIs
StatePublished - Dec 1 2006

Keywords

  • FLT3
  • Inhibitiors
  • KRN383
  • PKC412

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations. FLT3 in AML: Much more to learn about biology and optimal targeting'. Together they form a unique fingerprint.

  • Cite this